P ostinterventional remodeling is a critical determinant of long-term efficacy of percutaneous coronary interventions. Restenosis is characterized by acute elastic recoil and intimal hyperplasia attributable to inflammation, smooth muscle cell (SMC) proliferation, and extracellular matrix turnover. 1 Under hypercholesterolemic conditions, this is accompanied by influx and accumulation of low-density lipoprotein (LDL) cholesterol in the vessel wall that becomes oxidized and taken up by macrophages. Thereby these macrophages become foam cells and initiate a process of accelerated atherosclerosis.
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Under hypercholesterolemic conditions, this is accompanied by influx and accumulation of low-density lipoprotein (LDL) cholesterol in the vessel wall that becomes oxidized and taken up by macrophages. Thereby these macrophages become foam cells and initiate a process of accelerated atherosclerosis. 2 Previously, we and others described an important causal role for extracellular toll-like receptors (TLRs) in postinterventional remodeling. It has been shown that TLR4 and the MyD88-dependent pathway play an important role in restenosis and postinterventional accelerated atherosclerosis. [3] [4] [5] [6] Similarly, a crucial role for TLR2 has been described. 7 TLRs, as part of the innate immune system, are pattern recognition receptors known to recognize exogenous ligands that originate from bacteria or viruses as well as endogenous ligands. These endogenous ligands may be released after tissue damage or cell stress, processes that may be initiated by percutaneous coronary interventions. MyD88-dependent signaling is the dominant activation pathway of TLR signaling leading to nuclear factor-kappaB activation and upregulation of several proinflammatory cytokines. Because TLR2 and TLR4 are known to be expressed on the cell surface of vascular cells and activated in vascular disease processes via damageassociated molecular patterns as endogenous ligands, such as heat shock proteins, fibronectin containing extradomain A, tenascin-C, and high-mobility group box 1 (HMGB1), [8] [9] [10] [11] research in the cardiovascular field mainly focused on TLR2 and TLR4.
Little is known about the role of endosomal TLRs that are mostly studied for their recognition of viral/bacterial DNA and RNA fragments, and were originally considered absent in the healthy arterial vessel wall. 12 Activation of endosomal TLRs like TLR7 and TLR9 may lead to upregulation of interferon-α (IFN-α), interleukin-6 (IL-6), IL-12, or tumor necrosis factor-α (TNF-α) by innate immune cells (eg, macrophages). Recently, increased TLR7 mRNA was found in atheroma of human carotids. 13 Moreover, TLR9 was also found in human atherosclerotic plaques, 14 and arterial cells were responsive to TLR9 ligand. 15 Interestingly, it has been suggested that these receptors may also recognize self-DNA/ RNA that is exposed after cell stress and damage causing a sterile inflammatory reaction. [16] [17] [18] [19] TLR7 and TLR9 have also been shown to recognize immune complexes containing selfnucleic acids in autoimmune diseases. 16, 20 Percutaneous coronary interventions are considered to cause severe damage to the endothelium allowing influx of lipids and inflammatory cells into the vessel wall. Concurrently, deeper layers in the vessel wall experience severe stress, and cellular death at the place of intervention may cause a release of self-RNA/DNA or proteins that enhance the direct recognition of nucleic acids by intracellular TLRs or binding of these nucleic acids to intracellular TLR signaling regulators such as HMGB1. 21 Most interestingly, activation of TLR9 is also reported to increase the secretion of HMGB1, the endogenous ligand for TLR4. 22 Recently, we have identified a novel class of oligonucleotidebased compounds that act as dual antagonists of TLR7 and TLR9, and inhibit immune responses mediated through these receptors. 23, 24 In the present study, we focus on the therapeutic potential of targeting TLR7 and TLR9 to reduce postinterventional remodeling by preventing neointima formation and accelerated atherosclerosis. We illustrate the presence and upregulation of TLR7 and TLR9 and their colocalization with macrophages/foam cells in a murine model for neointima formation and accelerated atherosclerosis. A causal role of the TLR7/9 was studied in a murine model for postinterventional vascular remodeling in hypercholesterolemic apolipoprotein E*3-Leiden (apoE*3-Leiden) mice by the use of the TLR7/9 antagonist. Furthermore, we studied activation and antagonism of TLR7 and TLR9 on cultured macrophages and on foam cell formation using a novel TLR7/9 dual antagonist.
Materials and Methods
A detailed description of all materials and methods used is available in the online-only Data Supplement.
In brief, nonconstricted polyethylene cuffs were placed around the femoral arteries as a well-established model for neointima formation and accelerated atherosclerosis in hypercholesterolemic apoE3-Leiden mice. Immunohistochemistry for TLR7 and TLR9 was performed on paraffin-embedded sections of cuffed arteries of hypercholesterolemic apoE3-Leiden mice at t=0 and t=14. A TLR7/TLR9 dual antagonist was synthesized, and specificity was determined. We studied its effect on neointima formation and accelerated atherosclerosis in hypercholesterolemic apoE*3-Leiden mice after femoral arterial cuff placement by injecting the antagonist biweekly to get sufficient TLR7/9 blockade. Intimal lesions were analyzed for CD45, MAC3, and HMGB1 by immunohistochemistry. The antagonist was used to study the effect of blocking of TLR7/9 on macrophage activation and lipid accumulation in macrophages. Cytokine levels of TNF-α, IFN-γ-induced protein 10, IL-6, IL-12, and IL-10 were quantified by ELISA.
Results

Arterial Injury Leads to TLR7 and TLR9 Presence in the Vessel Wall
Little is known about the presence of TLR7 and TLR9 in the vessel wall after surgical intervention. Using immunohistochemical analysis, we explored whether TLR7 and TLR9 are expressed in cuffed remodeled arteries with neointimal lesions after 14 days and in noncuffed arteries of hypercholesterolemic apoE*3-Leiden mice, because TLR expression may differ among different arterial segments and also in response to vessel damage. 12, 13 Cuff placement for 14 days provoked severe neointimal thickening, and showed the presence of TLR7/9 profoundly in the tunica media of these arterial segments. Presence of either TLR7 or TLR9 could not be observed in noncuffed femoral arteries ( Figure 1A-1D) . Lesions in cuffed arteries of wild-type mice on a chow diet that consist dominantly of vascular SMCs were also negative for TLR7 and TLR9 ( Figure IA and IB in the online-only Data Supplement). Negative controls showed no staining ( Figure  IC in the online-only Data Supplement). The area with positive staining for both TLRs contained many macrophages, 
Inhibition of TLR7-and TLR9-Mediated Immune Responses by Antagonist
Splenocytes were cultured with 0.01 to 10 μg/mL of the dual TLR7/9 antagonist in combination with TLR3, TLR4, TLR7, or TLR9 agonist. The antagonist showed a dose-dependent reduced production of TNF, IL-6, and IFN-γ-induced protein 10 on either TLR7 or TLR9 activation. Activation of TLR4, the most robust signaling TLR, was not affected. Also cytokine production via activation of intracellular TLR3, which recognizes double-stranded RNA, was not affected by the antagonist ( Figure IIA -IID in the online-only Data Supplement). Culturing of splenocytes with the antagonist alone did not induce cytokine production (not shown). Administration of either TLR7 or TLR9 agonists alone to mice resulted in elevated inflammation indicated by increased levels of serum IL-12. Mice administered with antagonist before TLR7 or TLR9 agonist administration displayed lower levels of serum IL-12. TLR7/9 antagonist alone did not induce IL-12 expression, suggesting it does not induce immune responses. At the dose used, antagonist showed ≈64% and 85% inhibition of TLR9 and TLR7 agonist-induced IL-12 in mice, respectively. 
TLR7/9 Antagonist Reduced Neointima Formation and Accelerated Atherosclerosis
After detecting TLR7 and TLR9 presence in remodeled arteries, we focused on vascular remodeling. By in vivo administration of the antagonist, the causal involvement of TLR7/9 activation in intimal hyperplasia and accelerated atherosclerosis was assessed in hypercholesterolemic apoE*3-Leiden mice that underwent femoral arterial cuff placement, a widely applied model for restenosis. These mice were fed a Western-type diet, starting 3 weeks before surgery to induce hypercholesterolemia, and are well known to develop intimal lesions attributable to neointima formation and accelerated atherosclerosis. No significant difference in plasma total cholesterol levels was detected before surgery (control 9.3±0.60 mmol/L; TLR7/9 antagonist 9.0±0.46 mmol/L), nor had antagonist-treated mice significant altered cholesterol levels compared with control mice after 14 days at euthanizing (control 8.4±0.4 mmol/L; TLR7/9 antagonist 7.7±0.8 mmol/L). Hematoxylin-phloxine-saffron-stained sec tions were used to study vessel wall composition and showed a profound neointima formation with foam cell formation, which was clearly reduced in the antagonisttreated group. After quantification, we observed reduction in neointima formation of 66% (n=9 versus No differences in total vessel wall area or media area were found ( Figure 3A-3G ). In addition, we found a difference in IL-10 serum levels that were significantly higher in the antagonist-treated mice 14 days after cuff placement (0.43 versus 15.46 pg/mL; P=0.0003; Figure Figure 3H ). Nonspecific oligonucleotide administration not only had no effect on the number of circulating (Ly6C low ) monocytes or CD11b expression compared with PBS treatment, it also did not affect neointima formation ( Figure 3I and 3J).
TLR7/9 Blockade Reduced Macrophage/Foam Cell-Positive Area
As stated above, we observed a significant reduced MAC3-positive area. This was the case in both media (2445±327 μm 2 versus 661±199 μm 2 ; P=0.002) as well as neointima (268±59 μm 2 versus 26±9 μm 2 ; P=0.003), indicating less infiltration of macrophages that are importantly involved in the remodeling process. The percentage of positive area was also significantly reduced indicating a reduction of positive cells per μm 2 in both media as well as in the formed neointima. We also checked whether the effects observed in vivo could be related to the accumulation of total leukocytes in the lesions. Therefore, we quantified the area of the vessel segments that was positive of CD45, a pan-leukocyte marker. Vessels of the antagonist-treated mice showed a trend toward a reduced CD45-positive area which was significant in the neointima ( Figure 4A-4J) . 
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TLR7/9 Blockade Reduced Cytoplasmic HMGB1
Layers in the vessel wall undergo severe stress on intervention. Together with our finding of a significant decrease in macrophages, we searched for the presence of cytoplasmic or extracellular HMGB1 that is a marker of cell stress and macrophage activation. HMGB1 can be directly upregulated by TLR9 activation and is an important TLR7/9 signaling regulator and an endogenous TLR2/4 ligand. Kalinina et al previously showed that HMGB1 could be detected in atherosclerotic plaques. Furthermore, the authors showed that this was dominant in macrophages, and that in these macrophages there was a marked increase of HMGB1 in the cytoplasm. 25 Therefore, we performed analysis for the presence of cytoplasmic HMGB1 in the arterial wall. Because TLR7/9 was predominately expressed in the tunica media, where most macrophages/foam cells were present, the media area of the vessel segments that was positive for HMGB1 outside the nucleus was quantified. We found a significant decrease in the percentage of positive cytoplasmic HMGB1 in the media area of mice treated with antagonist (12.97±1.03% versus 7.80±1.28%; P=0.011; Figure 5A -5C). This is of special interest, because HMGB1 release is increased on TLR7/9 activation, regulates TLR7/9 signaling, and is known to function as an endogenous ligand for TLR2 and TLR4 ( Figure 5A -5C)
TLR7/9 Blockade Reduced Macrophage Proinflammatory Cytokine Production on TLR7/9 Activation
Macrophage activation and foam cell accumulation play a crucial role in lesion formation and accelerated atherosclerosis development after cuff placement. Because we found less macrophages and HMGB1 after blocking TLR7/9, we studied the effects of modulation of the TLR7/9 signaling in cultured bone marrow-derived macrophages. Bone marrow-derived macrophages were cultured for 7 days, and then stimulated with either TLR7 ligand imiquimod, TLR9 ligand C-phosphate-G (CpG)-oligodeoxynucleotide, or a combination of both for 24 hours. Activation was monitored by analysis of TNF-α expression, a key proinflammatory cytokine also known to be regulated in vivo after cuff placement. 26 Coadministration of TLR7/9 ligands with the antagonist caused a significant reduction in the production of TNF-α, whereas lipopolysaccharide-induced production of TNF-α was not altered by the antagonist ( Figure 6A ).
TLR7/9 Blockade Reduced Foam Cell Formation by Macrophages
Additionally to the direct effect of proinflammatory cytokine excretion by macrophages, we looked into the effect on lipid accumulation by macrophages because both processes are important in postinterventional remodeling. Because macrophage-induced cytokine production and foam cell formation are major contributors to neointima formation and accelerated atherosclerosis, we studied whether TLR7 activation in combination with native LDL could induce lipid uptake by macrophages as was shown previously for TLR9. Reduced TLR9 activation was previously described to be important in foam cell formation via oxidation of native LDL-cholesterol Figure 3 . Restenosis with accelerated atherosclerosis was initiated via cuff placement around the femoral artery in hypercholesterolemic apolipoprotein E*3-Leiden (apoE*3-Leiden) mice. Areas of femoral arteries were quantified by using 6 sections per vessel of each mouse. A mean of these 6 sections was used as the outcome of arterial remodeling per mouse. Outcomes of analysis are expressed in μm 2 (mean±SEM). Mice treated with the antagonist showed a significant reduction in neointima formation compared with controls (A). Antagonist-treated mice also showed a decrease in percentage of lumen stenosis (B) and a beneficial intima/media ratio (C). Neither total vessel wall area nor media area were altered (D and E). Representative hematoxylinphloxine-saffron (HPS; F) and Weigert elastin (G) stained cross sections of control mice and antagonist-treated mice 14 days after cuff placement. Number of circulating Ly6c low monocytes (corrected for total white blood cell count; H). Expression of adhesion molecule CD11b on Ly6c low monocytes (I). Neointima formation of cuffed mice treated with PBS, control oligo, and toll-like receptors 7 and 9 (TLR7/9) antagonist (J). *P<0.05. Statistical analysis was performed by use of a nonparametric MannWhitney test, *P<0.05. MFI indicates mean fluorescence intensity. 
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that normally is not capable of causing foam cell formation. 27 Furthermore, we were interested in whether our antagonist could block this process efficiently like it did on inflammation with only the agonists. Presence of native LDL with TLR7 stimulation alone caused lipid accumulation shown by positive Oil Red O staining in the macrophages whereas native LDL-cholesterol alone showed no staining at all ( Figure 6A and 6B). The use of antagonist showed a clear reduction in lipid uptake, and thus foam cell formation indicated less intracellular Oil Red O staining in the fixed macrophages ( Figure  6B -6E). TLR9 activation and blockade in the presence of LDL gave the same results, and was described previously 27, 28 (data not shown). Foam cells, formed by oxidized LDL (oxLDL) uptake of macrophages, die of releasing lipids, intracellular molecules, and necrotic debris which can further activate the remaining macrophages via endosomal receptors like TLR7/ TLR9. 29 Therefore, we cultured macrophages in the presence of oxLDL cholesterol ( Figure 6F ) to check whether the antagonist also could influence this lipid accumulation if we combined oxLDL administration with the antagonist. Oil Red O staining was found in the oxLDL-treated macrophages, whereas in combination with the antagonist showed only a few slightly positive cells ( Figure 6F and 6G) . To see whether this effect was dependent on influx or efflux of lipids, we analyzed expression of scavenger receptor CD36 and IL-10 production. CD36 scavenger receptor expression was not different (positive CD36 macrophages; control 41.48% versus antagonist 41.32%; Figure V in the online-only Data Supplement), however we noticed significant change in IL-10 levels ( Figure 6G ) indicating effects on lipid efflux whereas IL-10 enhances lipid efflux via the peroxisome proliferator-activated receptor-γ-liver X receptor-ATP-binding cassette subfamily A member 1/ATP-binding cassette subfamily G member 1 pathway.
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Discussion
The present study describes the role of a novel TLR7/9 dual antagonist in restenosis and accelerated atherosclerosis in mice. Individual presence of both TLR7 and TLR9 was noticed in femoral arteries of hypercholesterolemic apoE*3-Leiden mice with neointimal lesions and accelerated atherosclerosis after 14 days. These have to be infiltrating cells (eg, macrophages), whereas normal arteries or arterial lesion from normal mice that consist dominantly of vascular SMC stained negative for both TLRs and macrophages. In vivo administration of antagonist showed a significant reduction in neointima formation with a beneficial intima/media ratio in hypercholesterolemic apoE*3-Leiden mice. Moreover, blockade of TLR7/9 signaling led to a reduction in CD45-and MAC3-positive cells in both media as well as in the neointimal lesions, and we notice a decrease in cytoplasmic HMGB1 indicating a decrease in cellular stress and a difference in serum IL-10. In vitro, macrophages showed a significant increase in TNF-α production on TLR7 or TLR9 activation that was reduced after receiving TLR7/9 dual antagonist. Administration with TLR7 ligand imiquimod or TLR9 agonist CpG caused lipid accumulation in macrophages that could be sufficiently blocked by the antagonist. Moreover, oxLDL-induced foam cell formation was inhibited by antagonist, possibly via upregulation of IL-10.
Previously, we and others described involvement of TLR2 and TLR4 in postinterventional neointima formation. 3, 6, 7 Recently, a protective role for intracellular receptor TLR3, important in recognition of double-stranded RNA, was found in vascular remodeling. 31 Neointima formation attributable to postinterventional remodeling is strongly mediated by local activation and physiological changes, such as increased wall stress, cell damage, and inflammation. In the present study, we were able to notice the presence of TLR7 and TLR9 in Figure 5 . Presence of cytoplasmic highmobility group box 1 (HMGB1) in the injured vessel wall of hypercholesterolemic apolipoprotein E*3-Leiden (apoE3*-Leiden) mice 14 days after surgery. Sections were stained for HMGB1. Positive staining in areas of femoral arteries was quantified by using 6 sequential sections per artery of each mouse. A mean of positive staining of these 6 sections was used as the outcome of positive immunostaining per mouse. Outcome of cytoplasmic HMGB1 analysis in percentage (mean±SEM) of area of media (A). Representative pictures of HMGB1 staining in control mice (B) and antagonisttreated mice (C). Statistical analysis was performed with a nonparametric MannWhitney test, *P<0.05. TLR7/9 indicates toll-like receptors 7 and 9.
the postinterventional remodeled arteries whereas noncuffed vessels show no presence of these TLRs at all. This can probably be related to leukocytes that express these TLRs and infiltrate the vessel wall as a result of the damage of the intervention such as macrophages, and start to clear apoptotic cells and infiltrated lipids. The level of TLR expression may vary among different vessel specimens and may be influenced by these changes. 12 Other studies in addition to the present showed TLR7 expression in atheroma of carotids 13 and TLR9 presence in human atherosclerotic plaques 14 that may be activated via unmethylated CpG motifs from bacteria. 32 Furthermore, DNA from 17 different bacterial genera that can activate TLR9 was found in atherosclerotic carotids, 15 together indicating a possibly important contribution of these pattern recognition receptors to vascular remodeling.
Blocking TLR7/9 signaling by antagonist strongly inhibited neointima formation thereby reducing the percentage of lumen stenosis. Neointima formation is strongly mediated by SMC proliferation/migration and macrophage activation and lipid uptake. Because TLR7/9 presence could not be detected in undamaged arteries, it is unlikely that there is a direct activation of SMC. However, indirect activation of SMC is still possible via cytokines produced by leukocytes which express these TLRs. Our results may be explained, at least in part, by the difference in IL-10 production. On the other hand, TLR7 and TLR9 stimulation by their ligands causes a strong increase in the upregulation of TNF-α, which is important in postinterventional vascular remodeling, indicating a direct influence of TLR7/9 activation on inflammation. This response was nicely blocked by the antagonist in macrophages. Furthermore, we observed lower levels of HMGB1 in the cytoplasm after cuff placement in the antagonist-treated mice, thereby reducing its effect via direct activation of TLR2/4 and activation of intracellular TLRs via its binding to their nucleic acid ligands. 21, 33 Moreover, there were significantly fewer numbers of macrophages/foam cells present in media as well as neointima.
Activation of TLR7/9 leads to nuclear factor-kappaBmediated upregulation of proinflammatory cytokines. Furthermore, it is known that TLR9 activation causes release of nuclear HMGB1 that may become available in the cytoplasm or even outside the cell, where it is known to act as TLR2 and TLR4 ligand and was seen in macrophages in atherosclerotic plaques. 22, 25, 33, 34 Not only can this release be initiated on cell stress but also on activated macrophages that are capable of releasing HMGB1. 34, 35 Previously, we were able to detect HMGB1 in remodeled vein grafts in and outside the nucleus. 4 On cuff placement, we noticed the presence of HMGB1 in the cytoplasm as well. Others previously showed that CpG-oligodeoxynucleotide stimulates macrophages to secrete HMGB1, and extracellular HMGB1 is known to accelerate the delivery of CpG-oligodeoxynucleotides to its receptor, leading to a TLR9-dependent enhancement of IL-6, IL-12, and TNF-α. 22 Interestingly, HMGB1 is also known as a regulator of TLR7/9 signaling itself because the absence of HMGBs also severely impairs the activation of TLR3, TLR7, and TLR9 by their cognate nucleic acids. 21 Therefore, these intracellular TLRs are thought to play a very important role in autoimmune and other inflammatory diseases. 20, 21 Our data confirm causal involvement of TLR7 and TLR9 in vascularrelated diseases, and development of a novel TLR7/9 dual antagonist may have important implications for understanding and treatment of exacerbation periods of other inflammatory diseases such as rheumatoid arthritis and after vascular interventions that cause direct vessel damage.
Blocking TLR7/9 signaling leads to a reduction in inflammation and reduced lipid accumulation. The role for TLR7/9 may therefore indicate regulation of cell stress and thereby providing activation of macrophages to start scavenging lipids, dying cells, and attracting more leukocytes to the inflammatory hazard. Our results confirm macrophage activation via TLR7/9 ligands and show a decrease of the presence of macrophages in the vessel wall after cuff placement in the TLR7/9 antagonist-treated mice.
Several studies have demonstrated the effect of intracellular TLR activation on lipid uptake. 27, 28, 36, 37 Both TLR7 and TLR9 agonists cause upregulation of adipocyte differentiationrelated protein that is involved in lipid droplet formation in macrophages. 38 TLR9 was previously described to be involved in foam cell formation via upregulation of nicotinamide adenine dinucleotide phosphate oxidase 1, lectin-type oxLDL receptor 1, and perilipin 3. 27, 28 This foam cell formation was nuclear factor-kappaB-and IFN regulatory factor 7-dependent, and can be countered via liver X receptor activation. 37 Both nuclear factor-kappaB and IFN regulatory factor 7 are also important mediators of TLR7 signaling, and additionally we show that TLR7 stimulation in the presence of LDL leads to lipid uptake in macrophages. Our data show that blocking of TLR7 receptor results in no lipid uptake in macrophages that receive only LDL. Interestingly, the antagonist was capable of decreasing lipid accumulation of oxLDL in macrophages probably via IL-10. This might be attributable to altered efflux of lipids rather than decreased influx because CD36 expression is not altered whereas IL-10, like in vivo, is upregulated. Macrophage IL-10 is known to enhance the efflux of cholesterol. 30 Different mechanisms, directly related to TLR signaling, can be involved in changing IL-10 levels. Martin et al 39 showed that glycogen synthase kinase 3 can differentially regulate TLR-mediated cytokine production. In the normal TLR activation situation, there is little phosphatidylinositol 3-kinase stimulation, and glycogen synthase kinase 3 primarily remains constitutively active promoting the expression of IL-12. Alternative situations, with different pathogenic stimuli or blocking antagonists (small molecule inhibitors, RNA inhibitors), can lead to TLR-dependent activation of phosphatidylinositol 3-kinase and thereby inhibition of glycogen synthase kinase 3 that causes a decrease in IL-12 production and an increase in IL-10 production. Woodgett and Ohashi 40 have provided a nice overview about this glycogen synthase kinase 3 in TLR signaling. Alternatively, it was previously described that TLR4 activation can cause an increase of HMGB1 in macrophages, and that this HMGB1 is capable of reducing IL-10 levels. 41 oxLDL triggers inflammatory signaling through a heterodimer of TLR 4 and TLR6. Assembly of this newly identified heterodimer is regulated by signals from the scavenger receptor CD36. 42 Foam cells die of releasing lipids, intracellular molecules, and necrotic debris which can further activate the remaining macrophages via endosomal receptors like TLR7/TLR9. 29 Although HMGB1 can also be upregulated via TLR9 activation and it further enhances TLR7/9 activation, this might be a mechanism that causes the differences seen in IL-10 levels. Previously, it was already shown on regulatory T cells that additional TLR9 activation could inhibit IL-10 synthesis. 43 Further studies are needed to fully elucidate the mechanisms causing differences in IL-10 levels in relation to TLR signaling and blockade.
In summary, we observed upregulation of TLR7/9 expression during arterial restenosis and reduced macrophage activation and foam cell formation after TLR7/9 blockade, which was accompanied with increase in IL-10 production. Additional blocking of TLR7/9 leads to a reduction in neointima formation, increased IL-10 production, reduced macrophage presence in the lesions as well as less HMGB1 release, indicating the important role of TLR7 and TLR9 in postinterventional remodeling via reducing inflammation as well as lipid accumulation, thereby making it an interesting therapeutic target to reduce restenosis and accelerated atherosclerosis after vascular intervention. 
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